Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers

Gynecologic Oncology

Volumn 112, Issue 3, 2009, Pages 475-480

  Lee, Yoo Kyung ^a   Park, Noh Hyun ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

Ovarian neoplasm; p53; PTEN; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; FEMALE; GENE OVEREXPRESSION; GROUPS BY AGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY ADENOCARCINOMA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 60449113166     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.11.031     Document Type: Article

References (42)

1. Jemal A., Thomas A., Murray T., and Thun M. Cancer statistics, 2002. CA Cancer J. Clin. 52 (2002) 23-47
2. Kristensen G.B., and Trope C. Epithelial ovarian carcinoma. Lancet 349 (1997) 113-117
3. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. Jama 273 (1995) 491-497
4. Friedlander M.L. Prognostic factors in ovarian cancer. Semin Oncol. 25 (1998) 305-314
5. Hartmann L.C., Podratz K.C., Keeney G.L., Kamel N.A., Edmonson J.H., Grill J.P., et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J. Clin. Oncol. 12 (1994) 64-69
6. Milner B.J., Allan L.A., Eccles D.M., Kitchener H.C., Leonard R.C., Kelly K.F., et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res. 53 (1993) 2128-2132
7. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
8. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95 (1998) 29-39
9. Yamada K.M., and Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J. Cell Sci. 114 (2001) 2375-2382
10. Kanamori Y., Kigawa J., Itamochi H., Sultana H., Suzuki M., Ohwada M., et al. PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy. Int. J. Cancer 100 (2002) 686-689
11. Minaguchi T., Yoshikawa H., Oda K., Ishino T., Yasugi T., Onda T., et al. PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin. Cancer Res. 7 (2001) 2636-2642
12. Risinger J.I., Hayes K., Maxwell G.L., Carney M.E., Dodge R.K., Barrett J.C., et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin. Cancer Res. 4 (1998) 3005-3010
13. Anreder M.B., Freeman S.M., Merogi A., Halabi S., and Marrogi A.J. p53, c-erbB2, and PCNA status in benign, proliferative and malignant ovarian surface epithelial neoplasms: a study of 75 cases. Arch. Pathol. Lab. Med. 123 (1999) 310-316
14. Bedolla R., Prihoda T.J., Kreisberg J.I., Malik S.N., Krishnegowda N.K., Troyer D.A., et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin. Cancer Res. 13 (2007) 3860-3867
15. Brun J.L., Feyler A., Chene G., Saurel J., Brun G., and Hocke C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol. Oncol. 78 (2000) 21-27
16. Fallows S., Price J., Atkinson R.J., Johnston P.G., Hickey I., and Russell S.E. P53 mutation does not affect prognosis in ovarian epithelial malignancies. J. Pathol. 194 (2001) 68-75
17. Niwa K., Itoh M., Murase T., Morishita S., Itoh N., Mori H., et al. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br. J. Cancer 70 (1994) 1191-1197
18. Shahin M.S., Hughes J.H., Sood A.K., and Buller R.E. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 89 (2000) 2006-2017
19. Sood A.K., Sorosky J.I., Dolan M., Anderson B., and Buller R.E. Distant metastases in ovarian cancer: association with p53 mutations. Clin. Cancer Res. 5 (1999) 2485-2490
20. Reles A., Wen W.H., Schmider A., Gee C., Runnebaum I.B., Kilian U., et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin. Cancer Res. 7 (2001) 2984-2997
21. Klemi P.J., Pylkkanen L., Kiilholma P., Kurvinen K., and Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76 (1995) 1201-1208
22. Ferrandina G., Fagotti A., Salerno M.G., Natali P.G., Mottolese M., Maneschi F., et al. p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br. J. Cancer 81 (1999) 733-740
23. Green J.A., Berns E.M., Coens C., van Luijk I., Thompson-Hehir J., van Diest P., et al. Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). Eur. J. Cancer 42 (2006) 2539-2548
24. Havrilesky L., Darcy M., Hamdan H., Priore R.L., Leon J., Bell J., et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 21 (2003) 3814-3825
25. Freihoff D., Kempe A., Beste B., Wappenschmidt B., Kreyer E., Hayashi Y., et al. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br. J. Cancer 79 (1999) 754-758
26. Nassif N.T., Lobo G.P., Wu X., Henderson C.J., Morrison C.D., Eng C., et al. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene 23 (2004) 617-628
27. Zhou X.P., Gimm O., Hampel H., Niemann T., Walker M.J., and Eng C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol. 157 (2000) 1123-1128
28. Fei G., Ebert M.P., Mawrin C., Leodolter A., Schmidt N., Dietzmann K., et al. Reduced PTEN expression in gastric cancer and in the gastric mucosa of gastric cancer relatives. Eur. J. Gastroenterol. Hepatol. 14 (2002) 297-303
29. Torres J., Navarro S., Rogla I., Ripoll F., Lluch A., Garcia-Conde J., et al. Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissues. Eur. J. Cancer 37 (2001) 114-121
30. Davidson B., Hadar R., Schlossberg A., Sternlicht T., Slipicevic A., Skrede M., et al. Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum. Pathol. 39 (2008) 87-95
31. Kurose K., Zhou X.P., Araki T., Cannistra S.A., Maher E.R., and Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am. J. Pathol. 158 (2001) 2097-2106
32. Wang Y., Kristensen G.B., Helland A., Nesland J.M., Borresen-Dale A.L., and Holm R. Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am. J. Clin. Pathol. 124 (2005) 392-401
33. Lee J.I., Soria J.C., Hassan K.A., El-Naggar A.K., Tang X., Liu D.D., et al. Loss of PTEN expression as a prognostic marker for tongue cancer. Arch. Otolaryngol. Head Neck Surg. 127 (2001) 1441-1445
34. Tachibana M., Shibakita M., Ohno S., Kinugasa S., Yoshimura H., Ueda S., et al. Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer 94 (2002) 1955-1960
35. Schondorf T., Gohring U.J., Roth G., Middel I., Becker M., Moser N., et al. Time to progression is dependent on the expression of the tumour suppressor PTEN in ovarian cancer patients. Eur. J. Clin. Invest. 33 (2003) 256-260
36. Stambolic V., MacPherson D., Sas D., Lin Y., Snow B., Jang Y., et al. Regulation of PTEN transcription by p53. Mol. Cell 8 (2001) 317-325
37. Kim J.S., Lee C., Bonifant C.L., Ressom H., and Waldman T. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol. Cell Biol. 27 (2007) 662-677
38. Cully M., You H., Levine A.J., and Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6 (2006) 184-192
39. Maehama T., and Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273 (1998) 13375-13378
40. Zhou M., Gu L., Findley H.W., Jiang R., and Woods W.G. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res. 63 (2003) 6357-6362
41. Nenutil R., Smardova J., Pavlova S., Hanzelkova Z., Muller P., Fabian P., et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J. Pathol. 207 (2005) 251-259
42. Lassus H., Leminen A., Lundin J., Lehtovirta P., and Butzow R. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol. Oncol. 91 (2003) 504-512